PDLI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
PDL BioPharma Inc's revenue per share for the three months ended in Dec. 2013 was $0.64. PDL BioPharma Inc's revenue per share for the trailing twelve months (TTM) ended in Dec. 2013 was $2.83.
During the past 12 months, the average Revenue Per Share Growth Rate of PDL BioPharma Inc was 7.60% per year. During the past 3 years, the average Revenue Per Share Growth Rate was 12.90% per year. During the past 5 years, the average Revenue Per Share Growth Rate was 13.10% per year. During the past 10 years, the average Revenue Per Share Growth Rate was 9.80% per year.
During the past 13 years, PDL BioPharma Inc's highest 3-Year average Revenue Per Share Growth Rate was 997.90% per year. The lowest was -88.70% per year. And the median was 14.00% per year.
Revenue per Share is the amount of Revenue per outstanding share of the companys stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
PDL BioPharma Inc's Revenue Per Share for the fiscal year that ended in Dec. 2013 is calculated as
|Revenue Per Share (A: Dec. 2013 )||=||Revenue (A: Dec. 2013 )||/||Total Shares Outstanding (A: Dec. 2013 )|
PDL BioPharma Inc's Revenue Per Share for the quarter that ended in Dec. 2013 is calculated as
|Revenue Per Share (Q: Dec. 2013 )||=||Revenue (Q: Dec. 2013 )||/||Total Shares Outstanding (Q: Dec. 2013 )|
PDL BioPharma Inc Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2013 was 0.62 (Mar. 2013 ) + 0.94 (Jun. 2013 ) + 0.63 (Sep. 2013 ) + 0.64 (Dec. 2013 ) = $2.83 Mil.
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth: Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
PDL BioPharma Inc Annual Data
|per share rev||1.01||1.52||1.33||1.59||1.75||1.73||1.93||2.04||2.56||2.78|
PDL BioPharma Inc Quarterly Data
|per share rev||0.50||0.49||0.55||0.89||0.57||0.62||0.62||0.94||0.63||0.64|